The role of vasoactive intestinal peptide in pulmonary diseases

被引:7
作者
Zhong, Hong-Lin [1 ]
Li, Pei-Ze [1 ]
Li, Di [1 ]
Guan, Cha-Xiang [1 ]
Zhou, Yong [1 ]
机构
[1] Cent South Univ, Sch Basic Med Sci, Dept Physiol, Changsha 410078, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
Vasoactive intestinal peptide; Pulmonary arterial hypertension; Chronic obstructive pulmonary disease; Acute respiratory distress syndrome; Lung cancer; CYCLASE-ACTIVATING POLYPEPTIDE; VIP RECEPTOR AGONISTS; ARTERIAL-HYPERTENSION; SMOOTH-MUSCLE; IN-VITRO; ANTIINFLAMMATORY ACTIVITY; SELECTIVE ANTAGONIST; MEDIATED INHIBITION; MICE LACKING; LUNG;
D O I
10.1016/j.lfs.2023.122121
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Vasoactive intestinal peptide (VIP) is an abundant neurotransmitter in the lungs and other organs. Its discovery dates back to 1970. And VIP gains attention again due to the potential application in COVID-19 after a research wave in the 1980s and 1990s. The diverse biological impacts of VIP extend beyond its usage in COVID-19 treatment, encompassing its involvement in various pulmonary and systemic disorders. This review centers on the function of VIP in various lung diseases, such as pulmonary arterial hypertension, chronic obstructive pulmonary disease, asthma, cystic fibrosis, acute lung injury/acute respiratory distress syndrome, pulmonary fibrosis, and lung tumors. This review also outlines two main limitations of VIP as a potential medication and gathers information on extended-release formulations and VIP analogues.
引用
收藏
页数:16
相关论文
共 156 条
[1]   Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease [J].
Abad, C ;
Martinez, C ;
Juarranz, MG ;
Arranz, A ;
Leceta, J ;
Delgado, M ;
Gomariz, RP .
GASTROENTEROLOGY, 2003, 124 (04) :961-971
[2]   Agonists that stimulate secretion promote the recruitment of CFTR into membrane lipid microdomains [J].
Abu-Arish, Asmahan ;
Pandzic, Elvis ;
Kim, Dusik ;
Tseng, Hsin Wei ;
Wiseman, Paul W. ;
Hanrahan, John W. .
JOURNAL OF GENERAL PHYSIOLOGY, 2019, 151 (06) :834-849
[3]   VIP-dependent increase in F508del-CFTR membrane localization is mediated by PKCε [J].
Alcolado, Nicole ;
Conrad, Dustin J. ;
Rafferty, Sara ;
Chappe, Frederic G. ;
Chappe, Valerie M. .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2011, 301 (01) :C53-C65
[4]   Cystic fibrosis transmembrane conductance regulator dysfunction in VIP knockout mice [J].
Alcolado, Nicole G. ;
Conrad, Dustin J. ;
Poroca, Diogo ;
Li, Mansong ;
Alshafie, Walaa ;
Chappe, Frederic G. ;
Pelis, Ryan M. ;
Anini, Younes ;
Xu, Zhaolin ;
Hamidi, Sayyed ;
Said, Sami I. ;
Chappe, Valerie M. .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2014, 307 (02) :C195-C207
[5]   RELAXATION OF CAT TRACHEOBRONCHIAL AND PULMONARY ARTERIAL SMOOTH-MUSCLE BY VASOACTIVE INTESTINAL PEPTIDE - LACK OF INFLUENCE BY PEPTIDASE INHIBITORS [J].
ALTIERE, RJ ;
DIAMOND, L .
BRITISH JOURNAL OF PHARMACOLOGY, 1984, 82 (02) :321-328
[6]   Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice [J].
Athari, Seyyed Shamsadin ;
Pourpak, Zahra ;
Folkerts, Gert ;
Garssen, Johan ;
Moin, Mostafa ;
Adcock, Ian M. ;
Movassaghi, Masoud ;
Ardestani, Mehdi Shafiee ;
Moazzeni, Seyed Mohammad ;
Mortaz, Esmaeil .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 791 :811-820
[7]   Fluid secretion by submucosal glands of the tracheobronchial airways [J].
Ballard, Stephen T. ;
Spadafora, Domenico .
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2007, 159 (03) :271-277
[8]   INTESTINAL SECRETION - STIMULATION BY PEPTIDES [J].
BARBEZAT, GO ;
GROSSMAN, MI .
SCIENCE, 1971, 174 (4007) :422-+
[9]   Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension [J].
Benza, Raymond L. ;
Gomberg-Maitland, Mardi ;
Demarco, Teresa ;
Frost, Adaani E. ;
Torbicki, Adam ;
Langleben, David ;
Pulido, Tomas ;
Correa-Jaque, Priscilla ;
Passineau, Michael J. ;
Wiener, Howard W. ;
Tamari, Mayumi ;
Hirota, Tomomitsu ;
Kubo, Michiaki ;
Tiwari, Hemant K. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (11) :1345-1354
[10]  
Berger William E, 2005, Expert Opin Drug Deliv, V2, P965, DOI 10.1517/17425247.2.6.965